Ce
Celgene (BMS)
Summit NJFounded 19868,000 employees
Private CapbiotechAcquiredHematologyOncologyImmunology
Platform: Revlimid
Market Cap
N/A
All Drugs
4
Clinical Trials
7
Failed / Terminated
4
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Datonesiran | CEL-9579 | NDA/BLA | 1 | PD-1 | Prostate CaUC | ||
| Kemamavacamten | CEL-5235 | Preclinical | 2 | AHR | MCLBCC | ||
| Talafotisoran | CEL-7456 | NDA/BLA | 1 | PRMT5 | Meso | ||
| Mirivorutinib | CEL-9492 | Phase 3 | 3 | CD38 | RSVEoE |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (7)